SCHEMBL23536333

SCHEMBL23536333

NC1CCN(c2ccc(Cl)cc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR2 P30874 2/20 0.45
ALDH1A1 P00352 3/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
DRD4 P21917 1/20 0.41
GRM2 Q14416 1/20 0.41
POLB P06746 1/20 0.41
HTR3A P46098 2/20 0.41
PHGDH O43175 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
MEN1 O00255 1/20 0.41
HTR3B O95264 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
KMT2A Q03164 1/20 0.41
HTR3D Q70Z44 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29931979 1.00 SSTR2 (0.45) SSTR2ALDH1A1HTTLMNAKDM4E
SCHEMBL14465783 0.84 NOTUM (0.54) SSTR2ALDH1A1HTTLMNAKDM4E
SCHEMBL28867416 0.83 GRM2 (0.41) ALDH1A1HTTLMNAKDM4EDRD4
SCHEMBL4539952 0.83 ALDH1A1 (0.45) ALDH1A1HTTLMNAKDM4EPHGDH
SCHEMBL16146343 0.81 ALDH1A1 (0.65) SSTR2ALDH1A1HTTLMNAKDM4E
SCHEMBL12074106 0.81 ALDH1A1 (0.59) SSTR2ALDH1A1HTTLMNAKDM4E
SCHEMBL24628365 0.80 ALDH1A1 (0.58) ALDH1A1HTTLMNAKDM4EDRD4
SCHEMBL13419247 0.80 SSTR2 (0.43) SSTR2ALDH1A1HTTLMNATSHR
SCHEMBL3853464 0.80 DRD2 (0.60) ALDH1A1DRD4GRM2
SCHEMBL25964466 0.80 GRM5 (0.46) DRD4GRM2PHGDHGRM5NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 SSTR2 879/4885ALDH1A1 3737/4885HTT 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.